{"schema_version":"secwatch.filing_event.v1","accession":"0001559053-25-000042","form_type":"8-K","ticker":"PRTA","cik":"0001559053","company_name":"PROTHENA CORP PUBLIC LTD CO","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.733768+00:00","generated_at":"2026-05-16T23:40:54.001016+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Prothena Q3 net loss $36.5M, nine-month loss $222.5M on charges; pipeline advances","bullets":["Net loss for Q3 2025 was $36.5M ($0.68/sh) vs $59.0M ($1.10/sh) in Q3 2024; nine-month loss $222.5M ($4.13/sh) vs $64.4M ($1.20/sh).","Revenue fell to $2.4M in Q3 2025 from $1.0M in Q3 2024; nine-month revenue $9.7M vs $133.0M primarily from BMS collaboration.","Cash and equivalents $331.7M; no debt. FY2025 guidance: net cash used $170-178M, year-end cash ~$298M midpoint.","Roche to initiate Phase 3 PARAISO prasinezumab trial for Parkinson's by end 2025; Novo Nordisk started Phase 3 CLEOPATTRA for coramitug in ATTR-CM.","EGM on Nov 19 to vote on share capital reduction to support potential 2026 share redemption program; up to $105M in clinical milestones by end 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001559053-25-000042","json":"https://secwatch.observer/filing/0001559053-25-000042.json","markdown":"https://secwatch.observer/filing/0001559053-25-000042.md","text":"https://secwatch.observer/filing/0001559053-25-000042.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1559053/000155905325000042/0001559053-25-000042-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1559053/000155905325000042/prta-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:40:54.001016+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}